News Releases | Maravai LifeSciences Holdings LLC

Date	Title and Summary	Additional Formats
May 26, 2021	Maravai LifeSciences Announces June 2021 Investor Conference Schedule SAN DIEGO, May 26, 2021 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, is scheduled to participate in the following virtual investor conferences during the month of June.
May 10, 2021	Maravai Lifesciences Reports First Quarter Financial Results and Updates 2021 Financial Guidance SAN DIEGO, May 10, 2021 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai)(NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the first quarter ended March 31, 2021.
May 5, 2021	Maravai LifeSciences Announces Investor Conference Schedule for the Month of May 2021 SAN DIEGO, May 05, 2021 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, is scheduled to participate in the following virtual investor conferences during the month of May.
April 13, 2021	Maravai LifeSciences To Host Earnings Conference Call on Monday, May 10, 2021 SAN DIEGO, April 13, 2021 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its first quarter 2021 financial and operating results after the market closes on
April 12, 2021	Maravai LifeSciences Announces Closing of Secondary Offering of Class A Common Stock by Selling Stockholders and Full Exercise of the Underwriters’ Option to Purchase Additional Shares SAN DIEGO, April 12, 2021 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI) , a global provider of life science reagents and services to researchers and biotech innovators, today announced the closing of a public offering of 20,700,000 shares of Maravai’s Class A
April 7, 2021	Maravai LifeSciences Announces Pricing of an Upsized Secondary Offering of Class A Common Stock by Selling Stockholders SAN DIEGO, April 07, 2021 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI) , a global provider of life science reagents and services to researchers and biotech innovators, today announced the pricing of an upsized public offering of 18,000,000 shares of Maravai’s
April 5, 2021	Maravai LifeSciences Announces Launch of Proposed Secondary Offering of Class A Common Stock by Selling Stockholders SAN DIEGO, April 05, 2021 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI) , a global provider of life science reagents and services to researchers and biotech innovators, today announced the commencement of a public offering of its Class A common stock by certain
April 5, 2021	Maravai LifeSciences Announces Preliminary Unaudited First Quarter Revenues and Income From Operations Range SAN DIEGO, April 05, 2021 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai or the Company) (NASDAQ: MRVI) , a global provider of life science reagents and services to researchers and biotech innovators, today provided preliminary unaudited revenue and Income from Operations
March 15, 2021	Maravai LifeSciences Offers End-to-End mRNA Production with the Launch of TriLink BioTechnologies' Plasmid DNA Manufacturing Services New integrated offering will help to meet expected increases in global demand by simplifying and accelerating production of GMP-grade mRNA product for downstream vaccine and therapeutic manufacturing SAN DIEGO, March 15, 2021 (GLOBE NEWSWIRE) -- Maravai LifeSciences (NASDAQ: MRVI), a global
March 2, 2021	Maravai LifeSciences Reports Fourth Quarter and Full Year 2020 Financial Results and Initiates 2021 Financial Guidance SAN DIEGO, March 02, 2021 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the fourth quarter and the full year ended December 31,